ICYMI, some of this week’s featured content includes the newest regulatory updates for cemiplimab for BCC and upadacitinib for PsA. Plus, stories on practice management, webinar recaps, and more.
A study found WaterWipes, a baby wipe comprised of 99.9% water and a drop of fruit extract, helped reduce facial pressure injuries (FPI) caused by prolonged wear of personal protective equipment (PPE).
The pro-inflammatory transcription factor is critical for the expression of IL-23, which is known to play a role in psoriasis.
The National Psoriasis Foundation has updated its guidance statements for individuals living with psoriatic disease during the COVID-19 pandemic.
In the first part of our 3-part recap series of our Roadmap to Recovery webinar, panelists discussed how the dermatology practice changed during COVID-19 and what changes they plan on keeping.
New TrichoTest aims to help clinicians diagnose and treat alopecia.
Vivace microneedling device receives FDA clearance on 2MHz radiofrequency setting.
The FDA has approved a single-dose pre-filled pen for dupilumab (Dupixent, Sanofi and Regeneron) for at-home administration.
COSMOS phase 3b study data demonstrated the effectiveness of guselkumab in patients diagnosed with psoriatic arthritis.
DermTech offers a new way to detect skin cancer without patients having to go under the knife.
Suneel Chilukuri, MD, FAAD, FACMAS, takes Dermatology Times® inside his practice, Refresh Dermatology located in Houston, Texas, to demonstrate how they separate themselves from competitors.
In this month's Legal Eagle column, David J. Goldberg, MD, JD, dives into wrong-site surgeries and malpractice lawsuits.
In this month's Cosmetic Conundrums column, Dermatology Times® Chief Medical Editor Zoe Diana Draelos, MD, discusses allergies from skin care products and how to prevent adverse reactions.
It’s always a good time to do a financial revIew. You’ll make sure your savings and investments are aligned with your goals and reduce income taxes.
In the second part of our 3-part recap series of our Roadmap to Recovery webinar, panelists discuss what aesthetic procedures dermatology practices can add to their existing list to increase profit and patient satisfaction.
The FDA announces it did not meet the June 25 PDUFA action date on the sNDA for active psoriatic arthritis treatment, upadacitinib.
The European Commission has approved cemiplimab for the treatment of locally advanced or metastatic basal cell carcinoma in adults.
This week’s edition of The Mainstream Patient features stories about face mapping, benzene contamination in sunscreen, natural retinol, ceramides in skin care, plus more.